Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARsentan in VASCulitis
NCT05630612Phase 2Active, not recruiting
- Sponsor
- University of Edinburgh
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sparsentan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by University of Edinburgh. Started Dec 2022; status: active, not recruiting.
02
Drugs
sparsentan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05630612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630612.